An interventional study of Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders and Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders in Hematological Malignancy and Bone Marrow Failure Syndrome, sponsored by University of British Columbia. Completed at 1 site in Canada. Per ClinicalTrials.gov, last updated 2018-01-26.
Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment
Among 80 studies in Hematologic Neoplasms with a site in Canada — 15 open to participants now, 26 under way, 5 of them phase 3. Hematologic Neoplasms · Canada.
Among the 80 studies in Hematologic Neoplasms with a site in Canada, this one is the 56th largest by enrollment of the 68 interventional ones that give a count, is one of 8 that started in 2009, is one of 13 with no phase, and was the 10th registered.
1,444 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.
Browse Hematologic Neoplasms studies →15 of the 80 studies in Hematologic Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
CSL Behring · Sites in Canada, United States, Belgium and 8 more countries
Kura Oncology, Inc. · Sites in Canada, United States, Australia and 14 more countries
Swedish Orphan Biovitrum · Sites in Canada, United States, France and 5 more countries
Ottawa Hospital Research Institute · Sites in Canada
University of British Columbia · Sites in Canada, United States
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 313 Hematologic Neoplasms studies recruiting now, 208 (66%) set no upper age limit and 78 (25%) stop at 75 or younger; 80 take children under 18; 34 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 24 · Phase 3 16
First in 1998; this study’s year is marked. 8 started in 2009.
This study's enrollment of 27 is below the median of 46 across 1,044 interventional studies indexed under Hematologic Neoplasms.
Median enrollment 84 across the 68 interventional studies, 350 across the 11 observational. Of the 47 that completed or were terminated, 17 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 80 have an industry lead sponsor. The 10 most frequent:
University of British Columbia is the lead sponsor of 1,339 studies on the registry; 259 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of British Columbia has 3 studies filed under Hematologic Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Hematologic Neoplasms with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04448184Phase 3Ottawa Hospital Research InstitutePlatelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial) | 2027-02 |
| NCT02862275National Cancer Institute (NCI)Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer | 2026-11-21 |
| NCT06782373Swedish Orphan BiovitrumA Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | 2026-12-30 |
Among the 80 studies in Hematologic Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients must have a confirmed diagnosis at The Vancouver General Hospital or the BCCA-Vancouver.
Eligible patients will have one of the following underlying diseases:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders · Radiation: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders · Procedure: Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis. DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x * Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x * Fludarabine dose adjustment: 70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight. UCB Infusion
DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
To determine the safety and efficacy of multiple cord blood transplantation in patients with hematological malignancy.
Time frame: 1 year
To determine the 100-day treatment related mortality (TRM), complete remission rate and the 2-year progression free and overall survival rate for patients under going this treatment.
Time frame: 100 days
To determine the incidence of grades II-IV and grades III-IV acute GVHD and incidence of limited and extensive chronic GVHD.
Time frame: 1 year
To measure time to immunologic reconstitution as defined by normal numbers of T and B-cells and normal immunoglobulin synthesis
Time frame: 1 year
To determine rate of hematologic engraftment following umbilical cord blood transplantation with 1-2 cord blood units using total body irradiation & fludarabine as transplant conditioning regimen & cyclosporine/MMF as graft-vs-host disease prophylaxis
Time frame: 1 year
The record gives a start of May 2009, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →